A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

NCT05706506 on ClinicalTrials.gov · last registry update 2024-12-13

An unusually large phase 4: 152 participants, more than double the 75 typical for the stage. The sponsor logged completion for 31 October 2023. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c). tirzepatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 152
Started: 2023-03-08
Primary completion: 2023-10-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Type 2 Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.